Project Description

Aplex Bio

Aplex Bio develops next-generation hyperplexed PCR solutions. The technology is able to detect more than 100 target molecules in a sample – simultaneously and with ultra-high sensitivity down to one copy. Aplex Bio currently offers a broad panel of validated targets from different pathogens like SARS-COV-2 and others, and are constantly increasing its target base.

Aplex is based in Stockholm and is lead by Umear Naseem who founded the company. Aplex Bio joined NOME in 2021.

Company details


More companies